NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/06/2022
Back to search
Official data from USPTO
PRELUDE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
12/06/2022
Trademark type
Combined
Nice classes
42
Filing date
05/31/2019
Registration date
12/06/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/06/2022
Last transaction
12/06/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/20/2017
First use in commerce
04/20/2017
Drawing code
3
Owner type
03
Owner location
Wilmington, DE, US
Examiner
DEFORD, JEFFREY S
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a series of DNA strands formed into an eight-pointed star shaped design, to the right of the design appears the word "PRELUDE" having the first letter capitalized and the word "THERAPEUTICS" in smaller capital block letters centered below "PRELUDE.".
Holders and representatives
Holders
P. I. (pessoa física)
Representatives
Lisa Bollinger Gehman BAKER & HOSTETLER LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development of drugs in the fields of oncologyhematologyautoimmune diseasesrare diseases; scientific research for medical purposes in the fields of oncologyhematologyautoimmune diseasesrare diseases; clinical research in the fields of oncologyhematologyautoimmune diseasesrare diseases; scientific research and development of pharmaceuticals and biopharmaceuticals for the treatment of cancerhematological diseasesautoimmune diseasesrare diseases; providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; genetic testing for scientific research; genetic research in the fields of oncologyhematologyautoimmune diseasesrare diseases; none of the foregoing in relation to or in the field of fertility
Publications
History of USPTO decisions and trademark events.
36 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/06/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/01/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/31/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/12/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/12/2022
IUAF
USE AMENDMENT FILED
09/29/2022
EISU
TEAS STATEMENT OF USE RECEIVED
09/29/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/10/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/15/2022
PUBO
PUBLISHED FOR OPPOSITION
03/15/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/23/2022
ALIE
ASSIGNED TO LIE
02/06/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/04/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/02/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/02/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/18/2021
GNFR
FINAL REFUSAL E-MAILED
08/18/2021
CNFR
FINAL REFUSAL WRITTEN
08/18/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
01/14/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
06/24/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/20/2019
GNSL
LETTER OF SUSPENSION E-MAILED
12/20/2019
CNSL
SUSPENSION LETTER WRITTEN
12/20/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/04/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/03/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/03/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/23/2019
GNRT
NON-FINAL ACTION E-MAILED
08/23/2019
CNRT
NON-FINAL ACTION WRITTEN
08/23/2019
DOCK
ASSIGNED TO EXAMINER
08/21/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/24/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/18/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/15/2019
NWAP
NEW APPLICATION ENTERED
06/04/2019
Continuous trademark protection
Get notified about every new filing that threatens PRELUDE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.